Manila Times Business
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the "Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new,
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Honk-Key Lock and Safe Celebrates Grand Opening of Its Grand Junction Storefront, Establishing a Full-Service Locksmith Grand Junction Residents and Businesses Can Reach for Safe, Vault, and Commercial Door Work
6h ago
Conifex Announces Voting Results
7h ago
New Era for Jessup University as Dr. Meghan Barnard Named President
7h ago
Nairobi International Financial Centre Authority Deepens Strategic Partnership With CHAINBLX SPC to Advance Africa’s AI, Innovation and Digital Capital Ecosystem
7h ago